NanoViricides, Inc. (OTCMKTS:NNVC) Rises on Production Facility Updates

The new week will reveal if NanoViricides, Inc. (OTCMKTS:NNVC) will keep last week’s optimism. The stock is still without a promotion, although press releases refresh the interest. The biotech company was bought up on volumes above $580,000, but adding just a slim 1.8% to $1.10. Mondays trading started on the positive side, so far. NNVC0819.png

Early on Monday, the company came in with a publicity message concerning its future production plans. It seems like NNVC is revving up to open a clinical-scale production facility in Shelton, CT. While the work on the production line is going smoothly, the facility will be finished at the end of this year, and production may take a while longer. ACTC0819.png

The flu season may turn investors to the NNVC stock as the company has an upcoming injectable antiviral drug in its portfolio. Even without outright sales of the drug, the stock could be boosted if NNVC is active with the press releases, and the flu season has boosted the stock of antiviral drug producers in the past.

Fundamentally, NNVC has all the right numbers to go on, and the challenge is to gradually improve those numbers:

  • $15.4 million cash
  • $17.8 million total assets
  • $7.7 million total liabilities
  • $3.6 million quarterly net loss
  • $36 million loss for 96 months

NNVC also warned that the building process may be delayed- and this may bode ill for the stock price, as biotech companies tend to suffer badly from bad news, especially if the expectation is for a smooth development without hitches.

NNVC is on its path to become a staple as an actively traded pharmaceutical penny stock, much like the other name often mentioned, Advanced Cell Technology, Inc. (OTCBB:ACTC). The ticker is stagnating, moving between 8 and 6 cents in the past months as the company has diluted its stock too much, and investors are getting tired of waiting for results.

In the case of biotech companies, stock experts warn against forming too emotional a relationship. The firms have good stories and can feed expectations for a long time, while time and sales eat at the value of investments. If you decide NNVC is for you, think well on your preferred time horizon and avoid investing sums you cannot afford to sink into the biotech sector.

You may also like...